(CercleFinance.com) – A phase III clinical study has shown that Lynparza, the cancer drug developed by AstraZeneca and Merck, ‘significantly’ improved the progression-free survival of patients with prostate cancer .
The trial showed that Lynparza plus abiraterone, a standard treatment for the disease, reduced the risk of it getting worse or dying by 34% compared with abiraterone alone.
The combination of the two drugs also made it possible to improve the median survival time without progression of the disease by 24.8 months, compared to 16.6 months for abiraterone.
The study focused on the first-line treatment of patients with metastatic castration-resistant prostate cancer and for whom the presence of LHRH receptors has or has not been confirmed.
These results were published in the New England Journal of Medicine (NEJM), specify AstraZeneca and Merck.
With approximately 375,000 deaths each year, prostate cancer is the second most common form of cancer in men.
Copyright © 2022 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
